Androgens and musculoskeletal symptoms among breast cancer patients on aromatase inhibitor therapy

Breast Cancer Research and Treatment

Volumn 130, Issue 2, 2011, Pages 569-577

  Gallicchio, Lisa ^a   MacDonald, Ryan ^a   Wood, Bethany ^a   Rushovich, Errol ^a   Helzlsouer, Kathy J ^a  

^a MERCY MEDICAL CENTER   (United States)

Author keywords

Androgens; Aromatase inhibitors; Breast cancer; Dehydroepiandrosterone sulfate; Musculoskeletal symptoms; Testosterone

Indexed keywords

ANDROGEN; ANDROSTENEDIONE; AROMATASE INHIBITOR; ESTRADIOL; ESTROGEN RECEPTOR; PRASTERONE SULFATE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ADULT; AGED; ANDROGEN BLOOD LEVEL; ANDROSTENEDIONE BLOOD LEVEL; ARTICLE; BREAST CANCER; COHORT ANALYSIS; CONTROLLED STUDY; ESTRADIOL BLOOD LEVEL; ESTROGEN BLOOD LEVEL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MUSCULOSKELETAL DISEASE; MUSCULOSKELETAL PAIN; PATIENT COMPLIANCE; POSTMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; SEX HORMONE DETERMINATION; SYMPTOMATOLOGY; TESTOSTERONE BLOOD LEVEL; UNITED STATES;

AGED; ANDROSTADIENES; ANDROSTENEDIONE; ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; BREAST NEOPLASMS; DEHYDROEPIANDROSTERONE SULFATE; FEMALE; HUMANS; MIDDLE AGED; MUSCULOSKELETAL PAIN; NITRILES; TESTOSTERONE; TRIAZOLES;

EID: 82955249033     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1611-2     Document Type: Article

References (23)

1. Geisler J, Haynes B, Anker G, Dowsett M, Lonning PE (2002) Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 20:751-757 (Pubitemid 34111382)
2. Goss PE, Strasser K (2001) Aromatase inhibitors in the treatment and prevention of breast cancer. J Clin Oncol 19:881-894 (Pubitemid 32119104)
3. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ et al (2005) Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 97:1262-1271 (Pubitemid 41535367)
4. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF et al (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365:60-62
5. Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T et al (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with pri-mary breast cancer. N Engl J Med 350:1081-1092 (Pubitemid 38298988)
6. Khan QJ, O'Dea AP, Sharma P (2010) Musculoskeletal adverse events associated with adjuvant aromatase inhibitors. J Oncol 2010
7. Chowdhury S, Pickering LM, Ellis PA (2006) Adjuvant aroma-tase inhibitors and bone health. J Br Menopause Soc 12:97-103 (Pubitemid 44420448)
8. Wierman ME, Basson R, Davis SR, Khosla S, Miller KK, Rosner W et al (2006) Androgen therapy in women: an Endocrine Society Clinical Practice guideline. J Clin Endocrinol Metab 91:3697-3710 (Pubitemid 44536831)
9. Kaergaard A, Hansen AM, Rasmussen K, Andersen JH (2000) Association between plasma testosterone and work-related neck and shoulder disorders among female workers. Scand J Work Environ Health 26:292-298
10. Finset A, Overlie I, Holte A (2004) Musculo-skeletal pain, psy-chological distress, and hormones during the menopausal transi-tion. Psychoneuroendocrinology 29:49-64 (Pubitemid 37298014)
11. Rossi E, Morabito A, Di RF, Esposito G, Gravina A, Labonia V et al (2009) Endocrine effects of adjuvant letrozole compared with tamoxifen in hormone-responsive postmenopausal patients with early breast cancer: the HOBOE trial. J Clin Oncol 27:3192-3197
12. Ingle JN, Buzdar AU, Schaid DJ, Goetz MP, Batzler A, Robson ME et al (2010) Variation in anastrozole metabolism and phar-macodynamics in women with early breast cancer. Cancer Res 70:3278-3286
13. Mathur RS, Moody LO, Landgrebe S, Williamson HO (1981) Plasma androgens and sex hormone-binding globulin in the evaluation of hirsute females. Fertil Steril 35:29-35 (Pubitemid 11168911)
14. Dixon JM, Renshaw L, Young O, Murray J, Macaskill EJ, Mc Hugh M et al (2008) Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in post-menopausal women with breast cancer. J Clin Oncol 26:1671-1676
15. Iveson TJ, Smith IE, Ahern J, Smithers DA, Trunet PF, Dowsett M (1993) Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancer. Cancer Res 53:266-270 (Pubitemid 23031835)
16. Tominaga T, Suzuki T (2003) Early phase II study of the new aromatase inhibitor YM511 in postmenopausal patients with breast cancer. Difficulty in clinical dose recommendation based on preclinical and phase I findings. Anticancer Res 23:3533-3542 (Pubitemid 36975462)
17. Stanway SJ, Palmieri C, Stanczyk FZ, Folkerd EJ, Dowsett M, Ward R et al (2011) Effect of tamoxifen or anastrozole on steroid sulfatase activity and serum androgen concentrations in post-menopausal women with breast cancer. Anticancer Res 31:1367-1372
18. Bajetta E, Martinetti A, Zilembo N, Pozzi P, La TI, Ferrari L et al (2002) Biological activity of anastrozole in postmenopausal patients with advanced breast cancer: effects on estrogens and bone metabolism. Ann Oncol 13:1059-1066
19. Morrison MF, Katz IR, Parmelee P, Boyce AA, Ten Have T (1998) Dehydroepiandrosterone sulfate (DHEA-S) and psychiat-ric and laboratory measures of frailty in a residential care pop-ulation. Am J Geriatr Psychiatry 6:277-284 (Pubitemid 28460122)
20. Aloisi AM, Bonifazi M (2006) Sex hormones, central nervous system and pain. Horm Behav 50:1-7 (Pubitemid 43792491)
21. Morales AJ, Nolan JJ, Nelson JC, Yen SS (1994) Effects of replacement dose of dehydroepiandrosterone in men and women ofadvancing age. J Clin Endocrinol Metab 78:1360-1367 (Pubitemid 24181005)
22. Bennett RM, Cook DM, Clark SR, Burckhardt CS, Campbell SM (1997) Hypothalamic-pituitary-insulin-like growth factor-I axis dysfunction in patients with fibromyalgia. J Rheumatol 24:1384-1389 (Pubitemid 27353385)
23. Mc Beth J, Silman AJ, Gupta A, Chiu YH, Ray D, Morriss R et al (2007) Moderation of psychosocial risk factors through dys-function of the hypothalamic-pituitary-adrenal stress axis in the onset of chronic widespread musculoskeletal pain: findings of a population-based prospective cohort study. Arthritis Rheum 56:360-371 (Pubitemid 46106210)